... from any ideas, methods, instructions or products referred to in the content or advertisements. 2024 Relapse Chronic myeloid leukemia Dasatinib Imatinib Discontinuation With the advent of BCR::ABL1 tyrosine kinase inhibitors (TKIs), the outcome of patients with chronic myeloid...

.../discontinuations occurred while on imatinib (36/69; 49%) and dasatinib (20/69; 29%). Most interruptions/discontinuations occurred due to side effects/intolerance (46/69; 67%); other reasons included a wish to conceive (6/69; 9%) and attempts to achieve treatment-free remission (TFR) (6/69; 9%). Interruptions due...

...Jiaqi Tan; Mengxing Xue; Jinlan Pan; Jiannong Cen; Xiaomei Qi; Ping Liu; Xiaohong Zhao; Pin Wu; Qinrong Wang; Dandan Liu; Yuejun Liu; Suning Chen; Zhi Wang We retrospectively evaluated the efficacy and safety of dasatinib among 48 Chinese patients with chronic phase chronic myeloid leukaemia...

...Mohamed Shanshal; Andrew Shakespeare; Seshadri Thirumala; Boyd Fenton; Donald P. Quick Dasatinib is a potent inhibitor of the altered tyrosine kinase activity in disease states associated with BCR/ABL1. This agent has been shown to exhibit broad off-target kinase inhibition and immunomodulating...

... Lorand-Metze; Katia Borgia Barbosa Pagnano Early reduction of BCR-ABL1 transcript levels has been associated with improved outcome in chronic myeloid leukemia (CML) treatment. We evaluated 54 chronic-phase CML patients treated with imatinib who switched therapy to dasatinib (n = 33) or nilotinib (n = 21...

..., instructions or products referred to in the content or advertisements. BCR-ABL inhibitor Chronic myeloid leukemia Dasatinib Imatinib Nilotinib Many patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) are currently treated with imatinib, a BCR-ABL tyrosine kinase...

... therapy with dasatinib, intrathecal chemotherapy and cranial irradiation. Subsequently, 168 days after allogeneic HSCT, he was started on dasatinib maintenance therapy to prevent a CNS relapse. Thirty-eight months after allogeneic HSCT, he has sustained a complete molecular response in both bone marrow...

... month of treatment. During the follow-up, his lymphocyte number doubled in <6 months. Based on previous reports, dasatinib was chosen instead of imatinib. After 6 months of treatment with 100 mg/day of dasatinib, the patient demonstrated a partial response, characterized by the regression of lymph...

... have undergone prior allo-HSCT. This report presents the case of a patient with a post-transplant persistent positive BCR/ABL value, who was treated with imatinib and dasatinib before a second allo-HSCT. The patient started taking nilotinib due to a persistent BCR/ABL value and residual mass in her...